Skip to content
sellModerate cluster of 3

Elizabeth Rozek sold $98k of SGMT

General Counsel and CCO at Sagimet Biosciences Inc.. 10,780 shares at an average of $9.13, traded Jul 21, 2025, filed Jul 23, 2025.

Warning score
40
Value
$98k
10,780 shares
Holdings after
183,726
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $98k at market
    +10
  • Share of holdings sold
    Sold 5.5% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SGMTOct 9, 2026 · close 8.93
Since filing Jul 23, 2025: -6.9%SPY +24.4% · excess -31.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-070013, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 21, 2025SOpen-market sale
Series A Common Stock
-10,780$9.13$98k183,726Jul 23, 2025

Related signals

Other insiders at Sagimet Biosciences Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
37Weak
SGMTsell 3
Sagimet Biosciences Inc.
Thierry Chauche
Chief Financial Officer
$7,033
1,312 shares
-8%
48Moderate
SGMTsell 3
Sagimet Biosciences Inc.
David Happel
President & CEO
$65k
12,101 shares
-2%
30Weak
SGMTsell 3
Sagimet Biosciences Inc.
Eduardo Bruno Martins
Chief Medical Officer
$20k
3,640 shares
-3%
24Weak
SGMTsell10b5-1
Sagimet Biosciences Inc.
George Kemble
Executive Chairman
$290k
37,688 shares
-32%
59Moderate
SGMTsell 3
Sagimet Biosciences Inc.
David Happel
President & CEO
$598k
65,478 shares
-9%
38Weak
SGMTsell 3
Sagimet Biosciences Inc.
Eduardo Bruno Martins
Chief Medical Officer
$76k
8,277 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Elizabeth Rozek sold $98k of SGMT | InsiderTell